Search

Your search keyword '"Tomiya, Tomoaki"' showing total 295 results

Search Constraints

Start Over You searched for: Author "Tomiya, Tomoaki" Remove constraint Author: "Tomiya, Tomoaki" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
295 results on '"Tomiya, Tomoaki"'

Search Results

1. Nationwide survey for patients with acute-on-chronic liver failure occurring between 2017 and 2019 and diagnosed according to proposed Japanese criteria

4. Significance of portal venous blood flow as a factor to determine liver function in patients with decompensated cirrhosis due to hepatitis C virus infection following achievement of sustained viral response by sofosbuvir plus velpatasvir

5. Portal venous blood flows determine liver function in patients with decompensated cirrhosis due to HCV infection receiving successful sofosbuvir/velpatasvir therapy

6. Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct‐acting antivirals

10. Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog

11. Significance of furosemide in patients with cirrhosis treated with or without zinc acetate hydrate supplementation

13. Autotaxin as a novel serum marker of liver fibrosis

16. High ubiquitous mitochondrial creatine kinase expression in hepatocellular carcinoma denotes a poor prognosis with highly malignant potential

18. Rho-kinase inhibitor prevents hepatocyte damage in acute liver injury induced by carbon tetrachloride in rats

20. Balloon‐occluded retrograde transvenous obliteration as a procedure to improve liver function in patients with decompensated cirrhosis

21. Furosemide as a factor to deteriorate therapeutic efficacy of rifaximin in patients with decompensated cirrhosis

22. Furosemide as a factor to deteriorate therapeutic efficacy of tolvaptan in patients with decompensated cirrhosis

23. Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells

24. Antagonism of sphingosine 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct-ligated rodents

26. Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate

28. Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus

29. Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate

31. Transforming growth factor-alpha (TGF α)-producing gastric carcinoma with acanthosis nigricans: An endocrine effect of TGF α in the pathogenesis of cutaneous paraneoplastic syndrome and epithelial hyperplasia of the esophagus

33. Ischemic preconditioning in liver pathophysiology

37. Abstracts of selected papers presented at the 79th general meeting of the Japanese Society of Gastroenterology March 29–31, 1993, Kyoto, Japan

38. Abstracts of selected papers presented at the 33rd Annual Meeting of the Japanese Society of Gastroenterology

39. Abstracts of selected papers presented at the 32nd Annual Meeting of the Japanese Society of Gastroenterology

40. A case of genotype‐3b hepatitis C virus in which the whole genome was successfully analyzed using third‐generation nanopore sequencing

41. Deteriorated outcome of recent patients with acute liver failure and late‐onset hepatic failure caused by infection with hepatitis A virus: A subanalysis of patients seen between 1998 and 2015 and enrolled in nationwide surveys in Japan

42. Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy

46. Plasma thrombin-antithrombin III complexes in the diagnosis of primary hepatocellular carcinoma complicating liver cirrhosis

48. Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy

49. Nationwide survey for acute liver failure and late-onset hepatic failure in Japan

50. Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct‐acting antivirals

Catalog

Books, media, physical & digital resources